Prevalence of fatty liver disease after liver transplantation and risk factors for recipients and donors

被引:5
作者
Horiuchi, Kentaro [1 ]
Kogiso, Tomomi [1 ]
Sagawa, Takaomi [1 ]
Taniai, Makiko [1 ]
Kotera, Yoshito [2 ]
Egawa, Hiroto [2 ]
Tokushige, Katsutoshi [1 ]
机构
[1] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Internal Med, 8-1 Kawada Cho,Shinju Ku, Tokyo 1628666, Japan
[2] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, 8-1 Kawada Cho,Shinju Ku, Tokyo 1628666, Japan
关键词
Fatty liver disease (FLD); Liver transplantation (LT); Everolimus (EVL); SIMPLE NONINVASIVE INDEX; NONALCOHOLIC STEATOHEPATITIS; SIGNIFICANT FIBROSIS; STEATOSIS; CYCLOSPORINE; TACROLIMUS; DIAGNOSIS; CIRRHOSIS; PREDICT;
D O I
10.1016/j.aohep.2022.100670
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction and objectives: Fatty liver disease (FLD) may develop in liver transplant recipients. We investigated the recipient and donor risk factors for FLD development after liver transplantation (LT).Methods: A total of 108 liver transplant recipients (54 men [50.0%]; median age, 52 [20-68] years) treated from 2011-2020 was enrolled. Three recipients died at < 3 months as a result of infection or blood flow impairment, and were excluded from the long-term FLD study. On evaluation of 88 prospective living donors, fatty liver was observed in 21. The prevalence and risk factors for FLD and survival were evaluated.Results: After LT, 28 of 105 recipients (26.7%) developed FLD. FLD was more common in patients with a high body mass index (BMI) and dyslipidemia (both p < 0.01), primary nonalcoholic steatohepatitis (p = 0.02), after living-donor LT (p = 0.03) and everolimus (EVL) use (p = 0.08). Factors predictive of FLD included EVL use and a high BMI (hazard ratios = 3.00 and 1.34; p = 0.05 and p < 0.01, respectively). Sixteen donors lost 6.5 kg (range: 2.0-16.0 kg) of body weight prior to LT. However, there were no cases of primary non -function, which did not affect the FLD prevalence. Development of FLD did not have a negative impact on LT outcome; the 5-year survival rate was 92.6%. Conclusions: Recipient factors were more important than donor factors for FLD onset after LT. (c) 2022 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:8
相关论文
共 34 条
  • [21] NAFLD and liver transplantation: Current burden and expected challenges
    Pais, Raluca
    Barritt, A. Sidney
    Calmus, Yvon
    Scatton, Olivier
    Runge, Thomas
    Lebray, Pascal
    Poynard, Thierry
    Ratziu, Vlad
    Conti, Filomena
    [J]. JOURNAL OF HEPATOLOGY, 2016, 65 (06) : 1245 - 1257
  • [22] Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis
    Patsenker, Eleonora
    Schneider, Vreni
    Ledermann, Monika
    Saegesser, Hans
    Dorn, Christoph
    Hellerbrand, Claus
    Stickel, Felix
    [J]. JOURNAL OF HEPATOLOGY, 2011, 55 (02) : 388 - 398
  • [23] Weight gain and obesity after liver transplantation
    Richards, J
    Gunson, B
    Johnson, J
    Neuberger, J
    [J]. TRANSPLANT INTERNATIONAL, 2005, 18 (04) : 461 - 466
  • [24] Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis
    Saeed, Naba
    Glass, Lisa
    Sharma, Pratima
    Shannon, Carol
    Sonnenday, Christopher J.
    Tincopa, Monica A.
    [J]. TRANSPLANTATION, 2019, 103 (11) : E345 - E354
  • [25] Metabolic Syndrome
    Samson, Susan L.
    Garber, Alan J.
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2014, 43 (01) : 1 - +
  • [26] Severe everolimus-induced steatohepatis: a case report
    Schieren, Gisela
    Boelke, Edwin
    Scherer, Axel
    Raffel, Andreas
    Gerber, Peter Arne
    Kroepil, Patric
    Schott, Matthias
    Hamilton, Jackson
    Hayman, Anne
    Knoefel, Wolfram Trudo
    Budach, Wilfried
    Matuschek, Christiane
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2013, 18
  • [27] Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
    Sterling, Richard K.
    Lissen, Eduardo
    Clumeck, Nathan
    Sola, Ricard
    Correa, Mendes Cassia
    Montaner, Julio
    Sulkowski, Mark S.
    Torriani, Francesca J.
    Dieterich, Doug T.
    Thomas, David L.
    Messinger, Diethelm
    Nelson, Mark
    [J]. HEPATOLOGY, 2006, 43 (06) : 1317 - 1325
  • [28] Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
    Tokushige, Katsutoshi
    Ikejima, Kenichi
    Ono, Masafumi
    Eguchi, Yuichiro
    Kamada, Yoshihiro
    Itoh, Yoshito
    Akuta, Norio
    Yoneda, Masato
    Iwasa, Motoh
    Yoneda, Masashi
    Otsuka, Motoyuki
    Tamaki, Nobuharu
    Kogiso, Tomomi
    Miwa, Hiroto
    Chayama, Kazuaki
    Enomoto, Nobuyuki
    Shimosegawa, Tooru
    Takehara, Tetsuo
    Koike, Kazuhiko
    [J]. JOURNAL OF GASTROENTEROLOGY, 2021, 56 (11) : 951 - 963
  • [29] Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society
    Umeshita, Koji
    Eguchi, Susumu
    Egawa, Hiroto
    Haga, Hironori
    Kasahara, Mureo
    Kokudo, Norihiro
    Sakisaka, Shotaro
    Takada, Yasutsugu
    Tanaka, Eiji
    Eguchi, Hidetoshi
    Uemoto, Shinji
    Ohdan, Hideki
    [J]. HEPATOLOGY RESEARCH, 2019, 49 (09) : 964 - 980
  • [30] URATA K, 1995, HEPATOLOGY, V21, P1317, DOI 10.1016/0270-9139(95)90053-5